Blunting brain tumor growth with immune activation

December 8, 2013

Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.

Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer – called glioblastoma, is 15 months. Less than five per cent of patients survive beyond five years.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumour samples and discovered that specialized immune cells in brain tumour patients are compromised. The researchers took this discovery and, in an animal model, identified a drug that is able to re-activate those immune cells and reduce brain tumour growth, thereby increasing the lifespan of mice two to three times. Their discovery will be published December 8th in the prestigious journal Nature Neuroscience.

Our brains normally contain specialized cells, called microglia, that defend against injury or infection. "Microglia are the brain's own dedicated immune system," explains Yong. "And in this study, we have formally demonstrated for the first time that these cells are compromised in living brain tumour patients."

As with other forms of cancer, brain tumours start as individual stem-like cells – called brain tumour initiating cells (BTICs). These cells quickly divide and grow, eventually forming a mass, or tumour. Yong and his team have discovered that the tumour disables microglia, permitting the rapid proliferation of BTICs, which ultimately leads to brain tumour growth.

In experimental subjects treated with Amphotericin B, the microglia cells(brown) are activated and they surround glioma stem cells and reduce their tumor growth. Credit: Drs. Susobhan Sarkar and Wee Yong

"We refer to this as the battle for the brain, in which early on in the disease, the microglia are trying to destroy the brain tumour initiating cells," says Yong. "But over the course of time, the tumour disables the microglia and we start to see more initiating cells and more rapid tumour growth. We have sought to tip the battle in favour of the brain to suppress the tumour."

In addition to discovering this mechanism, Yong and Sarkar also identified a drug - amphotericin B (AmpB) - to reactivate microglia that in an animal model, showed a significant reduction in brain tumour growth.

The drug they identified is a powerful agent that is already used clinically to treat severe fungal infections of the brain and spinal cord. "It's a rather harsh medication," says Yong. "But we have demonstrated that this drug can be used in very small doses where it is not only well tolerated, but it is also effective in re-programming microglia."

Yong and Sarkar hope this discovery will lead to clinical trials and ultimately to a new standard of care for brain tumour patients.

The finding has already garnered attention from researchers across Canada, including internationally recognized brain tumour scientist and neurosurgeon Dr. James Rutka.

"This research is highly significant as it implies that a commercially available drug, amphotericin B, which has never been used before for patients with gliomas, may be a novel treatment to consider in future trials of patients with this frequently lethal cancer," says Dr. Rutka, Professor and Chair, Department of Surgery, University of Toronto.

Related Stories

(Medical Xpress)—New research from the University of Adelaide has shown for the first time that the growth of brain tumours can be halted by a drug currently being used to help patients recover from the side effects of ...

Research at Lund University in Sweden gives hope that one of the most serious types of brain tumour, glioblastoma multiforme, could be fought by the patients' own immune system. The tumours are difficult to remove with surgery ...

A new scanning technique developed by Danish and US researchers reveals how susceptible patients with aggressive brain cancer are to the drugs they receive. The research behind the ground-breaking technique has just been ...

Cells of malignant brain tumours deceive our immune system so effectively that it starts working for them. But who lives by the sword, dies by the sword. Researchers from the Nencki Institute in Warsaw show how to deceive ...

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet in Sweden presents very promising results for the treatment of the cancer form multiple myeloma. ...

A new imaging tool developed by Boston scientists could do for the brain what the telescope did for space exploration. In the first demonstration of how the technology works, published July 30 in the journal Cell, the researchers ...

In a study conducted at UCLA, five men who had been completely paralyzed were able to move their legs in a rhythmic motion thanks to a new, noninvasive procedure that stimulates the spinal cord. It is believed to be the first ...

If you've had a good night's sleep, you are mentally more alert and your memory works more reliably. During sleep, a part of our forebrain called the prefrontal cortex remains active. It ensures that memories and learned ...

A study that took a novel approach to investigating factors affecting the emergence of symptoms of Huntington's disease (HD) has identified at least two genome sites that house variants that can hasten or delay symptom onset. ...